MTOR and cancer: ,91 In terms of integrated functional analysis, Luminal A and B and Her2-enriched cancer exhibits a slightly higher CS for the TSC/mTOR pathway in comparison of Basal-like BRCA, aligning with the role of Her2 expression in activating the PI3K-mTOR signaling in BRCA.33